ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.290
-0.250 (-7.06%)
At close: Dec 5, 2025, 4:00 PM EST
3.390
+0.100 (3.04%)
After-hours: Dec 5, 2025, 7:06 PM EST
ADC Therapeutics Employees
As of December 31, 2024, ADC Therapeutics had 265 total employees, including 263 full-time and 2 part-time employees. The number of employees decreased by 9 or -3.28% compared to the previous year.
Employees
265
Change (1Y)
-9
Growth (1Y)
-3.28%
Revenue / Employee
$283,808
Profits / Employee
-$629,966
Market Cap
407.56M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 265 | -9 | -3.28% |
| Dec 31, 2023 | 274 | -43 | -13.56% |
| Dec 31, 2022 | 317 | 5 | 1.60% |
| Dec 31, 2021 | 312 | 104 | 50.00% |
| Dec 31, 2020 | 208 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADCT News
- 3 days ago - ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript - Seeking Alpha
- 3 days ago - ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - PRNewsWire
- 4 days ago - ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial - PRNewsWire
- 5 days ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 26 days ago - ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update - PRNewsWire
- 4 weeks ago - ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 - PRNewsWire
- 5 weeks ago - ADC Therapeutics to Present at November Investor Conferences - PRNewsWire